A Phase 2 interventional study of Ipratropium Bromide and Normal Saline (Placebo) in Exercise-Induced Laryngeal Obstruction and Dyspnea During Activity, sponsored by Cook Children's Health Care System. Not yet recruiting at 1 site in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Cook Children's Health Care System · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 214 studies in Dyspnea with a site in United States — 31 open to participants now, 37 under way, 1 of them phase 3. Dyspnea · United States.
Among the 214 studies in Dyspnea with a site in United States, this one is the 68th largest by planned enrollment of the 151 interventional ones that give a count, is one of 11 that started in 2026, is one of 27 in phase 2, reaches primary completion later than 33 of the 36 other live ones, and was the 203rd registered.
895 studies on the registry are indexed under Dyspnea; 189 are open to participants now.
Browse Dyspnea studies →31 of the 214 studies in Dyspnea with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18–75 · Healthy volunteers
Pfizer · Sites in United States
Ages 18+
Hackensack Meridian Health · Sites in United States
Ages 27 wk–34 wk
Joseph C. Wu · Sites in United States
Ages 40+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 125 Dyspnea studies recruiting now, 68 (54%) set no upper age limit and 41 (33%) stop at 75 or younger; 18 take children under 18; 23 take healthy volunteers.
This study: 8 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
214 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 40 · Phase 3 16 · Phase 4 12
First in 1999; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 50 across 588 interventional studies indexed under Dyspnea.
Median enrollment 36 across the 151 interventional studies, 93 across the 62 observational. Of the 162 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 214 have an industry lead sponsor. The 10 most frequent:
Cook Children's Health Care System is the lead sponsor of 11 studies on the registry; 9 are open to participants now.
Cook Children's Health Care System has 1 study filed under Dyspnea — fewer than ten, so there is no comparison to draw.
13 of the studies in Dyspnea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05866952Tufts Medical CenterVentilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection | 2026-12 |
| NCT07386444Ohio State University Comprehensive Cancer CenterInspiratory Muscle Training for Breast Cancer Patients on Chemotherapy | 2026-12-31 |
| NCT06684119Children's Hospital Los AngelesPediatric Positive End Expiratory Pressure (PEEP) Titration Using Electrical Impedence Tomography (EIT) | 2027-01-01 |
| NCT06524856University of NebraskaThe Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser) | 2027-03-01 |
| NCT06977581PfizerA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | 2027-03-08 |
Add all 13 to your calendar (.ics) → With an account.
Among the 214 studies in Dyspnea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators propose a study that compares breathlessness and airway obstruction during intense exercise in 34 children and adolescents with Exercise-Induced Laryngeal Obstruction after breathing in ipratropium bromide or placebo. It is hypothesized that breathlessness and airway obstruction will be lower following breathing in ipratropium bromide compared with placebo.
Many children and adolescents struggle with breathing problems during exercise. These symptoms can lead them to underperform, quit sports, and in some cases, stop being active altogether. One under-recognized cause is Exercise-Induced Laryngeal Obstruction (EILO), a narrowing of the airway at the level of the voice box. Approximately 5-8% of adolescents and 20-40% of adolescent athletes have EILO, an estimated 4-6 million nationwide. The most common treatment for EILO is Speech Therapy, with or without Physical Therapy. Where available, this requires significant time and financial commitment from patients and their families to attend therapy sessions and complete at-home exercises.
Case reports as early as 1985 have suggested aerosolized ipratropium bromide as an effective EILO treatment. One larger study could not confirm this observation. However, this study used an outcome measure with low reliability and validity, did not use a placebo control, and administered a low dose of ipratropium bromide too close to exercise.
The investigators propose a study that compares breathlessness and airway obstruction during intense exercise in 34 children and adolescents with EILO following inhalation of a higher dose of nebulized ipratropium bromide with placebo. It is hypothesized that breathlessness and airway obstruction will be lower following inhalation of ipratropium bromide compared with placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Ipratropium Bromide in their first trial and Placebo in the second trial.
Drug: Ipratropium Bromide · Drug: Normal Saline (Placebo)
Participants will receive Placebo in their first trial and Ipratropium Bromide in the second trial.
Drug: Ipratropium Bromide · Drug: Normal Saline (Placebo)
Nebulized Ipratropium Bromide (500µg/2.5mL); one-time dose approximately 75 minutes before exercise, inhaled for 5-8 minutes
3 mL of nebulized 0.9% normal saline; one-time dose approximately 75 minutes before exercise, inhaled for 5-8 minutes
Visual Analogue Scale for Dyspnea (VAS-Dyspnea)
Shortness of breath assessed by a 0-100 Visual Analogue Scale for Dyspnea, where higher scores reflect greater breathlessness
Time frame: Day1 and Day 2
CLE grade scoring
Patient videos will be assessed for laryngeal obstruction by two expert reviewers. Blinded reviewers will grade the severity of glottic and supraglottic obstruction on a scale from 0 (no obstruction) to 3 (severe obstruction).
Time frame: Day 1 and Day 2
Plan to share: No — The investigators anticipate the institution's IRB/legal team will not approve sharing IPD.
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Dec 2029, 42 months later.
Of 23 phase 2 interventional studies under Dyspnea, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 77. This study's planned 42 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ipratropium
Cook Children's Health Care System